Business Wire

Global Payments Leader, Credorax, Rebrands As ‘Finaro’

Share

Leading smart payments provider and merchant acquiring bank, Credorax, has today announced its new company identity, Finaro.

Focusing on its core pillars of creating multi-dimensional solutions to simplify payments and going the extra mile for its merchants, Finaro empowers global commerce by providing the ideal solution for cross-border businesses with its cutting-edge technology and superior support.

The news of the rebranding bookends a strong 2021, with Finaro’s impressive 40% Year-on-Year Compound Annual Growth Rate. Founded in 2009, the company currently employs over 350 people, and is based in Israel and Malta, with presence in China Mainland, Hong Kong, the United States and across Europe.

Credorax has already been proven as a payments provider that facilitates its merchants’ growth and with the global fintech industry expected to skyrocket to $190bn by 2026, this rapidly accelerating trajectory creates the perfect environment for Finaro’s new brand to establish itself as a strong player amongst its peers. This huge growth in fintech has seen cross-border sales take more than a quarter of the entire ecommerce marketplace in Europe, highlighting the significance of a provider that can make multidimensional payments brilliantly simple.

Finaro serves over 5000 merchants around the world and in a wide variety of industries, including retail, digital goods and services, travel, hospitality, and mobility. Kiwi.com, Air Baltic, Wolt, Payrexx, Revolut, Go2Mobile and Hero Gaming are among its customers and across all verticals the trend is similar: all merchants are operating within very competitive markets and they are required to create perfect customer experiences. Led by a team of payments experts and solution-creators, Finaro is committed to absorbing the immense complexity of payments and delivering simplicity, so merchants are free to pursue their ambition, knowing they are covered.

“Our company success has always been built on our in-house, cutting-edge full stack platform as well as strong customer relationships, and constant product innovation. Our passionate team of solutions-creators with a can-do approach enable us to create brilliantly simple payment solutions for our merchants, said Igal Rotem, Chief Executive Officer for Finaro.

“Our evolution from Credorax to Finaro reflects the revolution our business has undertaken since joining the payments world 15 years ago and our rebranding is the next step in our growth as a company and on our path towards realizing our vision of commerce, untethered. I’m incredibly proud reveal our new brand identity as Finaro,” Igal continued.

“We came into this industry with a fresh view because we saw obstacles that needed getting beyond, and that’s what we have been doing ever since,” commented Moshe Selfin, Chief Operating & Chief Technology Officer for Finaro. “We pioneered a multidimensional approach to payments that untangles even the most wicked problems in the payments space, paving the way for new and exciting possibilities and giving our merchants a meaningful competitive advantage.”

“Branding is much more than just colours, logos and slogans - it’s about the essence of our company and how we are presented to the world externally. When developing our new brand Finaro, we crystalized our essence, and it was critical to establish our identity as a company that cares about its customers and can deliver the outstanding,” explains Achiya Fried, Chief Commercial Officer of Finaro, “We go the extra mile in flexibility and we co-create solutions with our clients, by providing cutting edge, multidimensional payments solutions, that untangle the complexity of payments. Our new brand, Finaro, reflects just that."

###ENDS###

About Finaro

Finaro is a global cross-border payment provider empowering international commerce through brilliantly simple payments. Our passionate team, exceptional tech capabilities, product innovation, and customer-centric approach enables us to simplify complexity and create multidimensional solutions that generate growth and enable peace of mind for our merchants. To learn more, visit www.finaro.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jenna Walker
jenna@skyparlour.com
07591 382 856

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes7.12.2022 10:39:00 CET | Press release

The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with empagliflozin compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes.1 When empagliflozin was added to other baseline treatments (diet, exercise, metformin and/or insulin) HbA1c was reduced by 0.84% compared with placebo at week 26 (95% CI –1.50 to –0.19; P=0.012).1 The results were presented today at the International Diabetes Federation (IDF) World Diabetes congress 20221, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005405/en/ The DINAMO (DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents) trial included youth aged 10-17 years with type 2 diabetes and HbA1c ≥6.5% and ≤10.5%. Participants were randomly assigned treatmen

Opening Ceremony Held for NTHU’s Center for Dissection Education and Research7.12.2022 10:00:00 CET | Press release

The opening ceremony for National Tsing Hua University (NTHU) in Taiwan’s Center for Dissection Education and Research, which cost over NT$100 million, was recently held. The ceremony included a memorial service for the cadaver donors. As an expression of gratitude, the first batch of students in the Post-baccalaureate Program in Medicine also offered Chinese bellflowers to the donors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005054/en/ Students of the Post-baccalaureate Program in Medicine at NTHU offering Chinese bellflowers to those who have donated their cadavers to the program. (Photo: National Tsing Hua University) At the ceremony, former NTHU president Hocheng Hong signed the first donation agreement, which indicates that the donor has unconditionally pledged his body for education and research after death, for the purposes of advancing medical science. Current NTHU president W. John Kao thanked Hocheng fo

BIOCORP Obtains 510(k) FDA Clearance for Mallya ®7.12.2022 07:30:00 CET | Press release

Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, announced today that they have received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: "This approval is a major achievement for BIOCORP and all of our employees who have been heavily involved in this regulatory process. This approval marks a historic achievement for BIOCORP as it allows the commercial launch of our Mallya device in the United States and illustrates BIOCORP's ability to meet the highest regulatory requirements. This news has been eagerly awaited by all our industry partners to commercialize Mallya in the world's largest diabetes market and we are delighted that U.S. patients will soon be able to benefit from Mallya's services. This regulatory milestone will have a positive

Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-109177.12.2022 07:11:00 CET | Press release

Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML). Be given to ODD, Delta-Fly Pharma, Inc. can be entitled to seven extra years of marketing exclusivity and receive some benefits such as R&D rebate by getting approval. DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed AML. A Phase 3 clinical study has been underway at MD Anderson Cancer Center in Texas and other major sites of Hematologic Cancer Treatment in USA. The company expects to complete the patients’ enrollment plan soon. Delta-Fly Pharma, Inc. focuses not only on cancer itself but on the whole conditions of cancer patients, and aims to deliver medicines that are recommendable for cancer patients and their families. Company profile Company name Delta-Fly Pharma, Inc. [Tokyo:4598] Capital 3352 million Japanese Ye

SLB Announces Pricing of Debt Tender Offer6.12.2022 22:05:00 CET | Press release

SLB (NYSE: SLB) today announced the consideration payable in connection with the previously announced offer (the “Offer”) by Schlumberger Holdings Corporation, an indirect wholly-owned subsidiary of SLB (“SHC”), to purchase for cash up to a certain amount of the notes listed in the table below (the “Notes”), pursuant to the terms and subject to the conditions set forth in the offer to purchase, dated November 21, 2022 (as may be amended or supplemented from time to time, the “Offer to Purchase”). Capitalized terms used but not defined in this press release have the meanings given to them in the Offer to Purchase. Title of Security CUSIP Numbers Acceptance Priority Level(1) Principal Amount Outstanding Principal Amount to be Purchased Early Tender Premium(1) Reference Security Bloomberg Reference Page Reference Yield Fixed Spread (basis points) Total Consideration (1)(2) 3.750% Senior Notes due 2024 806851AJ0 (144A) / U8066LAG9 (Reg S) 1 $750,000,000 $394,869,000 $30 2.500% U.S. Treasur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom